ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT01549886

Public ClinicalTrials.gov record NCT01549886. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 12:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

Study identification

NCT ID
NCT01549886
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Enrollment
5 participants

Conditions and interventions

Interventions

  • Moxtezafin Gadolinium Drug
  • Rituximab Drug
  • Y-90-Zevalin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2011
Primary completion
May 31, 2014
Completion
Apr 30, 2015
Last update posted
Oct 3, 2021

2011 – 2015

United States locations

U.S. sites
9
U.S. states
6
U.S. cities
9
Facility City State ZIP Site status
Alta Bates Summit Medical Center-Herrick Berkeley California 94704
Providence Saint Joseph Medical Center Burbank California 91505
Halifax Health- Center for Oncology Daytona Beach Florida 32114
Rush University Medical Center Chicago Illinois 60612
Loyola University Chicago Maywood Illinois 60153
Oncology Specialists Park Ridge Illinois 60068
University of Massachusetts - Worcester Worcester Massachusetts 01655
Hackensack Medical Center Hackensack New Jersey 07601
West Virginia University, WVU Healthcare Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01549886, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 3, 2021 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01549886 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →